FDA grants orphan drug designation to biologic therapy for Angelman syndrome

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has granted orphan drug designation to a microbiome-modifying biologic to treat Angelman syndrome, according to the manufacturer.

In a press release, Biom Pharmaceutical Corp. stated its formulation of Bi104, a novel therapeutic, aims to modulate the microflora and metabolite profile in the gut to reduce neuroinflammation in patients with the disease.

The FDA granted orphan drug designation to a microbiome-modifying biologic intended to treat Angelman syndrome. Image: Adobe Stock

Angelman syndrome is a rare neurodevelopmental disorder characterized by developmental delay, intellectual disability, speech impairment, and motor abnormalities which affects approximately 1 in 20,000 individuals worldwide. Currently, there is no specific treatment approved for preventing or controlling the condition.

“There is no doubt that we need innovative new approaches for these difficult-to-treat epilepsies,” Bobban Subhadra, MS, PhD, co-founder and president of Biom Pharmaceutical, said in the release. “Traditionally, these indications were overlooked and were underfunded, but a new wave of innovative drug development is in progress with gene therapy and siRNA-based technologies. I think modulating the gut microbiome is another novel treatment approach.”

Source link

error: Content is protected !!